LOGIN  |  REGISTER
Viking Therapeutics

GE HealthCare management to present at upcoming investor conferences

April 28, 2025 | Last Trade: US$69.34 1.00 -1.42

CHICAGO / Apr 28, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conferences.

  • Bank of America Securities Healthcare Conference in Las Vegas, NV – May 13, 2025 at 10:00 am CT / 11:00 am ET
  • Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL – June 10, 2025 at 9:00 am CT / 10:00 am ET

Webcasts of these events can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page